Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 1.00 |
| ▸ | RAF1 | P04049 | 4/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | IGF1R | P08069 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.72 |
| ▸ | BCR | P11274 | 1/20 | 0.72 |
| ▸ | SRC | P12931 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451324 | 0.95 | MAP2K1 (0.90) | MAP2K1RAF1MAPK3MAPK1IGF1R | |
| SCHEMBL6991654 | 0.93 | MAP2K1 (0.87) | MAP2K1RAF1MAPK3MAPK1IGF1R | |
| SCHEMBL6993386 | 0.93 | MAP2K1 (1.00) | MAP2K1RAF1MAPK3MAPK1IGF1R | |
| SCHEMBL4447752 | 0.92 | MAP2K1 (0.86) | MAP2K1RAF1MAPK3MAPK1IGF1R | |
| SCHEMBL25920182 | 0.92 | MAP2K1 (0.85) | MAP2K1RAF1MAPK3MAPK1EGFR | |
| SCHEMBL6995929 | 0.92 | MAP2K1 (0.85) | MAP2K1RAF1MAPK3MAPK1IGF1R | |
| SCHEMBL25920207 | 0.91 | MAP2K1 (0.83) | MAP2K1RAF1MAPK3MAPK1SRC | |
| SCHEMBL4457381 | 0.91 | MAP2K1 (1.00) | MAP2K1RAF1MAPK3MAPK1IGF1R | |
| SCHEMBL14116957 | 0.90 | MAP2K1 (0.82) | MAP2K1RAF1MAPK3MAPK1IGF1R | |
| SCHEMBL12618429 | 0.88 | MAP2K1 (0.79) | MAP2K1RAF1MAPK3MAPK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-12146196-B2 | C-RAF mutants that confer resistance to RAF inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-11-19 | — | — | US | claimed |
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-12 | — | — | US | claimed |
| US-20240293557-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-09-05 | — | — | US | claimed |
| US-20240093310-A1 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-21 | — | — | US | claimed |
| US-11788151-B2 | C-RAF mutants that confer resistance to RAF inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | claimed |
| US-11789022-B2 | MEK1 mutation conferring resistance to RAF and MEK inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | claimed |
| WO-2022266491-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-22 | — | — | WO | claimed |
| WO-2022261220-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-15 | — | — | WO | claimed |
| EP-3693741-B1 | MEDICAL USES INVOLVING C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | DANA FARBER CANCER INST INC (US) | 2022-01-05 | — | — | EP | claimed |
| US-20210085663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BIOMED VALLEY DISCOVERIES, INC. | 2021-03-25 | — | — | US | claimed |
| EP-3624896-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | Biomed Valley Discoveries, Inc. (US) | 2020-03-25 | — | — | EP | claimed |
| EP-3333575-B1 | C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | DANA FARBER CANCER INST INC (US) | 2020-02-26 | — | — | EP | claimed |
| CN-110799245-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2020-02-14 | — | — | CN | claimed |
| WO-2018213302-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2018-11-22 | — | — | WO | claimed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12522872-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2011112678-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110110891-A1 | Methods of Treating Hepatitis C Virus Infection | NIH-DEITR | 2011-05-12 | — | — | US | disclosed |
| WO-2010068738-A1 | MEK MUTATIONS CONFERRING RESISTANCE TO MEK INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | BCL3, MCL1, BCL2 | MAP2K1 1502/4885RAF1 1335/4885MAPK3 3685/4885 |
| US-20110110891-A1 | Methods of Treating Hepatitis C Virus Infection | HAVCR2, HCCS, HDGF | MAP2K1 939/4885RAF1 15/4885MAPK3 90/4885 |
| US-20240293557-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | MCL1, BCL3, CRBN | MAP2K1 3050/4885RAF1 1078/4885MAPK3 3412/4885 |
| US-20210085663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BRAF, NRAS, KRAS | MAP2K1 34/4885RAF1 4/4885MAPK3 26/4885 |
| US-11789022-B2 | MEK1 mutation conferring resistance to RAF and MEK inhibitors | BRAF, RAF1, NRAS | MAP2K1 38/4885RAF1 2/4885MAPK3 42/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | MAP2K1 40/4885RAF1 50/4885MAPK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.